Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

Company Overview

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key Stats

• Today's Range: $4.30 to $4.50
• 50-Day Range: $4.25 to $6.67
• 52-Week Range: $4.14 to $15.99
• Volume: 20,163 shs
• Average Volume: 54,933 shs
• Market Capitalization: $12.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Hold

Cadrenal Therapeutics Stock Analysis - MarketRank™

Cadrenal Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 518th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Cadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Cadrenal Therapeutics has a consensus price target of $13.00, representing about 200.2% upside from its current price of $4.33.

Amount of Analyst Coverage

Cadrenal Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($5.52) to ($3.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cadrenal Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cadrenal Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cadrenal Therapeutics has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.35% of the float of Cadrenal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cadrenal Therapeutics has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cadrenal Therapeutics has recently increased by 30.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cadrenal Therapeutics does not currently pay a dividend.

Dividend Growth

Cadrenal Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: -0.03

News Sentiment

Cadrenal Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Cadrenal Therapeutics this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for CVKD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cadrenal Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,154.00 in company stock.

Percentage Held by Insiders

26.09% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.92% of the stock of Cadrenal Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CVKD
• CIK: 1937993
• Web: www.cadrenal.com
• Phone: 904-300-0701
• Fax: N/A
• Employees: 4
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Cadrenal Therapeutics: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +200.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -411.03%
• Return on Assets: -275.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.68
• Quick Ratio: 2.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.17 per share
• Price / Book: 3.69

Miscellaneous

• Outstanding Shares: 2,868,000
• Free Float: 2,120,000
• Market Cap: $12.39 million
• Optionable: Not Optionable
• Beta: 1.59